Page 3 - Markl Levitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Highland Park man pleads not guilty to 18 child pornography charges Steven E. Habay Updated 7/15/2021 5:18 PM A 47-year-old Highland Park man pleaded not guilty this week to 18 counts of child pornography and two counts of aggravated battery to a peace officer. Steven E. Habay, of the 1500 block of Lancelot Avenue, appeared before Lake County Judge Mark L. Levitt at a hearing Tuesday.   He faces one count of reproducing child porn and 17 of possession, according to court documents. Highland Park police and Lake County state's attorney investigators searched Habay's home on May 26...

Mark L. Levitt will serve as chief judge of the 19th Judicial Circuit Court for a term beginning Jan. 3, 2022.

(1) Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is over 75% enrolled, with completion of enrollment expected in the coming weeks Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ -- RedHill Bi...

Credit: RedHill Biopharma Opaganib targets a human cell component involved in viral replication and is therefore expected to be effective against emerging viral variants with mutations in the spike protein Preliminary data from the non-powered U.S. Phase 2 study of opaganib demonstrated safety and positive efficacy data across key primary and secondary endpoints TEL AVIV, Israel and RALEIGH, NC, January 29, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) fo...

Share this article Share this article TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib [1] in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients. "Opaganib is a novel, or...